Clinical care and other categories posters: Incretin therapies

Clinical care and other categories posters: Incretin therapies P356Evaluation of the long‐term cost‐effectiveness of treatment switching from sitagliptin to liraglutide in subjects with Type 2 diabetes in the United KingdomA BARNETT1,2, G Subramanian3, S Arnoldini4, B Hunt4 and C Stentoft Hoxer31Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK, 2Heart of England NHS Foundation Trust, Birmingham, UK, 3Novo Nordisk Ltd., Gatwick, UK, 4Ossian Health Economics and Communications, Basel, SwitzerlandObjectives: The recent LIRA‐SWITCH trial showed that treatment switching from sitagliptin 100mg to liraglutide 1.8mg led to statistically significant and clinically relevant improvements in HbA1c and body mass index. The aim of this study was to assess the long‐term cost‐effectiveness of treatment switching from sitagliptin to liraglutide 1.8mg in patients with Type 2 diabetes in the United Kingdom.Methods: The QuintilesIMS CORE Diabetes Model Version 8.5+ (QuintilesIMS Health, Basel, Switzerland) was used to project costs and clinical outcomes over patients’ lifetimes. Baseline cohort characteristics and treatment effects were based on the randomised controlled LIRA‐SWITCH trial. Both future costs and clinical benefits were discounted at 3.5% per annum. Costs were accounted in pounds sterling (GBP [£]) and expressed in 2016 values.Results: Model projections showed improved quality‐adjusted life expectancy for patients with poor glycaemic control (HbA1c 7.5% to 9.5%) on http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetic Medicine Wiley

Clinical care and other categories posters: Incretin therapies

Loading next page...
 
/lp/wiley/clinical-care-and-other-categories-posters-incretin-therapies-nbf1hBJBMu
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Diabetic Medicine © 2018 Diabetes UK
ISSN
0742-3071
eISSN
1464-5491
D.O.I.
10.1111/dme.39_13571
Publisher site
See Article on Publisher Site

Abstract

P356Evaluation of the long‐term cost‐effectiveness of treatment switching from sitagliptin to liraglutide in subjects with Type 2 diabetes in the United KingdomA BARNETT1,2, G Subramanian3, S Arnoldini4, B Hunt4 and C Stentoft Hoxer31Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK, 2Heart of England NHS Foundation Trust, Birmingham, UK, 3Novo Nordisk Ltd., Gatwick, UK, 4Ossian Health Economics and Communications, Basel, SwitzerlandObjectives: The recent LIRA‐SWITCH trial showed that treatment switching from sitagliptin 100mg to liraglutide 1.8mg led to statistically significant and clinically relevant improvements in HbA1c and body mass index. The aim of this study was to assess the long‐term cost‐effectiveness of treatment switching from sitagliptin to liraglutide 1.8mg in patients with Type 2 diabetes in the United Kingdom.Methods: The QuintilesIMS CORE Diabetes Model Version 8.5+ (QuintilesIMS Health, Basel, Switzerland) was used to project costs and clinical outcomes over patients’ lifetimes. Baseline cohort characteristics and treatment effects were based on the randomised controlled LIRA‐SWITCH trial. Both future costs and clinical benefits were discounted at 3.5% per annum. Costs were accounted in pounds sterling (GBP [£]) and expressed in 2016 values.Results: Model projections showed improved quality‐adjusted life expectancy for patients with poor glycaemic control (HbA1c 7.5% to 9.5%) on

Journal

Diabetic MedicineWiley

Published: Jan 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off